Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Comparison of Cerb B2 expression and Ki-67 index with modified scarff-bloom-richardson grading system in invasive ductal carcinoma

Meric Emre Bostanci, Kursat Karadayi.




Abstract
Cited by 0 Articles

Aim: Breast cancer is the most frequent cancer among women. Cerb B2 is an oncogene that encodes a transmembrane glycoprotein known as HER-2 protein or receptor. Ki-67 is nuclear protein associated with cellular proliferation. In this study, we investigated the relationships between the histopathologic parameters in the “Modified Scarff-Bloom-Richardson” microscopic grading and expression of Cerb B2 and Ki-67 index gene in cases with invasive ductal carcinoma. Breast cancer is the most common type of cancer in women, but also the second most common cause of death after lung cancer.
Material and Methods: In this study examined 45 patients who were diagnosed with invasive ductal carcinoma between January 2017 and January 2019 in Sivas Cumhuriyet University, department of surgical oncology. Cases, Cerb B2 expression and Ki-67 index were retrospectively screened from pathology records
Results: Increased expression of Cerb B2 was statistically significant related with increased tubule formation, pleomorfism, mitosis rate, and histological grade (p=0.006, p=0.027, p

Key words: Cerb B2, invasive ductal carcinoma of the breast, Ki-67






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.